SLDB241220C10000
- 0.30
- 0.000.00%
Solid Biosciences Newsroom
J.P. Morgan Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $12
Solid Biosciences Price Target Maintained With a $15.00/Share by Chardan Capital
Solid Biosciences Is Maintained at Buy by Chardan Capital
Solid Biosciences Analyst Ratings
Barclays Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $15
A Quick Look at Today's Ratings for Solid Biosciences(SLDB.US), With a Forecast Between $15 to $20
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Privia Health Group (PRVA) and Jazz Pharmaceuticals (JAZZ)
Strategic Advancements and Optimized Approaches Drive Buy Rating for Solid Biosciences
Piper Sandler Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $16
William Blair Initiates Solid Biosciences(SLDB.US) With Buy Rating
Leerink Partners Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $28
Solid Biosciences: Buy Rating Reaffirmed Amid Market Skepticism and Upcoming SGT-003 Data Release
Piper Sandler Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $20
Solid Biosciences (SLDB) Gets a Buy From Piper Sandler
Chardan Capital Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $15
Buy Rating Justified for Solid Biosciences Amid Promising Gene Therapy Advances
Solid Biosciences Analyst Ratings
H.C. Wainwright Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $16
Buy Rating Affirmed for Solid Biosciences Amid Promising Early Data on SGT-003 DMD Therapy